{"id":"rina-s","safety":{"commonSideEffects":[{"rate":null,"effect":"Immune-related adverse events"},{"rate":null,"effect":"Infusion reactions"}]},"_chembl":{"chemblId":"CHEMBL297792","moleculeType":"Small molecule","molecularWeight":"464.57"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Rina-S is designed to bind and modulate multiple immune pathways to overcome tumor immune evasion. By targeting dual checkpoints, the drug aims to provide a more potent immune activation than single-checkpoint inhibitors, potentially improving efficacy in difficult-to-treat cancers.","oneSentence":"Rina-S is a bispecific antibody that simultaneously engages two immune checkpoints to enhance T-cell activation and anti-tumor immunity.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:32:14.366Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT07288177","phase":"PHASE2","title":"Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Genmab","startDate":"2026-01-30","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":240},{"nctId":"NCT07225270","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy","status":"RECRUITING","sponsor":"Genmab","startDate":"2026-03-16","conditions":"Ovarian Cancer, Platinum-sensitive Ovarian Cancer, PSOC","enrollment":528},{"nctId":"NCT05579366","phase":"PHASE1, PHASE2","title":"Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)","status":"RECRUITING","sponsor":"Genmab","startDate":"2022-12-07","conditions":"High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma","enrollment":764},{"nctId":"NCT07166094","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer","status":"RECRUITING","sponsor":"Genmab","startDate":"2025-11-28","conditions":"Endometrial Cancer, Recurrent or Progressive Endometrial Cancer","enrollment":544},{"nctId":"NCT06619236","phase":"PHASE3","title":"Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2025-02-07","conditions":"Platinum-resistant Ovarian Cancer","enrollment":530}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PRO1184","Rinatabart sesutecan","GEN1184","Rinatabart Sesutecan"],"phase":"phase_3","status":"active","brandName":"Rina-S","genericName":"Rina-S","companyName":"Genmab","companyId":"genmab","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rina-S is a bispecific antibody that simultaneously engages two immune checkpoints to enhance T-cell activation and anti-tumor immunity. Used for Advanced or metastatic solid tumors (Phase 3 development).","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}